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Background: Public awareness of hemolytic-uremic syndrome (HUS), especially related to Shiga toxin-producing
Escherichia coli (STEC), has increased in Europe in recent years; accentuated in Norway by a national outbreak in
2006 and in a European context especially by the 2011 outbreak originating in Germany. As STEC surveillance is
difficult due to diagnostic challenges in detecting non-O157 infections, surveillance of HUS can be used to indicate
the burden of STEC infection. Until 2006, notification of HUS to the Norwegian Communicable Disease Surveillance
System (MSIS) was based on microbiologically confirmed infection with enterohemorrhagic Escherichia coli (EHEC),
humanpathogenic STEC. In 2006, diarrhea-associated HUS (D+HUS) was made notifiable based on clinical criteria
alone. The incidence and etiology of HUS in children in Norway has not previously been described.
Methods: In order to assess the sensitivity of STEC and D+HUS surveillance and describe the incidence and etiology
of HUS in children in Norway, we conducted a nationwide retrospective study collecting data from medical records
from pediatric departments for the period 1999–2008 and compared them with data from MSIS. Descriptive
statistics are presented as proportions, median, average and mean values with ranges and as incidence rates,
calculated using population numbers provided by official registries.
Results: Forty-seven HUS cases were identified, corresponding to an average annual incidence rate of 0.5 cases per
100,000 children. Diarrhea-associated HUS was identified in 38 (81%) cases, of which the median age was 29 months,
79% were <5 years of age and 68% were girls. From 1999 to 2006, thirteen more diarrhea-associated HUS cases
were identified than had been notified to MSIS. From the change in notification criteria to 2008, those identified
corresponded to those notified. STEC infection was verified in 23 (49%) of the HUS cases, in which O157 was the
most frequently isolated sporadic serogroup.
Conclusions: Our results show that the incidence of HUS in children in Norway is low and suggest that D+HUS
cases may be underreported when notification requires microbiological confirmation. This may also indicate
underreporting of STEC infections.
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Hemolytic-uremic syndrome (HUS) is a clinical syndrome
characterized by microangiopathic hemolytic anemia, im-
paired renal function and excessive platelet consumption
leading to thrombocytopenia [1]. HUS is considered to be
the most common cause of acute kidney injury (AKI) in
European children, mainly affecting pre-school-aged
children [2-4]. In the long term, HUS is associated with
complications such as hypertension and end-stage renal
disease with a death rate of approximately 3–5% [3]. Based
on clinical presentation and probable etiology, HUS is
commonly divided into diarrhea-associated HUS (D+HUS)
and non-diarrhea-associated HUS (D−HUS), also called
atypical HUS. Recent classifications have suggested a more
specific approach based on causality and clinical associa-
tions [2]. Usually, around 90% of cases are D+HUS, while
10% are atypical HUS [5-9].
The most common cause of D+HUS in children is infec-
tion with Shiga toxin-producing Escherichia coli (STEC)
[1], although not all STEC-associated HUS (STEC-HUS)
cases present with diarrhea [7,10-12]. Shiga toxins are pro-
duced and released by STEC bacteria and are the main
cause of STEC-HUS [1]. There are two main types of
Shiga toxins, Shiga toxin 1 and Shiga toxin 2 (Stx 1 and
2). The latter is more frequently found in bacteria causing
HUS than Shiga toxin 1. Ruminants are the main reservoir
for STEC and infections are mainly food or waterborne.
In D−HUS, the most common causes are infection caused
by Streptococcus pneumoniae (SP-HUS) and genetic forms
of HUS [9].
HUS and STEC infections are under epidemiological
surveillance in the EU. In 2012, the European Commis-
sion updated the European case definition for STEC, re-
quiring laboratory confirmation of Stx or stx gene(s),
except when STEC O157 is directly isolated [13]. Sur-
veillance of HUS and STEC in many countries is based
on this case definition, requiring laboratory confirmation
prior to notification. There are certain challenges in the
surveillance of STEC. Far from all STEC infections are
treated by a physician, identification of the infectious
agent in mild infections might be judged unnecessary by
clinicians and until more recent years, verification of
non-O157 serogroups was difficult. Because of this,
some countries, including France, have previously used
surveillance of HUS to follow trends and identify out-
breaks of STEC infection [14]. This is based on STEC
being the causal factor in most HUS cases. In 2009,
3573 cases of STEC were reported in the EU, of which
half were caused by serogroup O157 [4]. In Europe and
America, this serogroup is most frequently isolated from
HUS patients [2,4,6,12,15], while O111 is dominant in
Australia [16]. Serotype O157:H7 is the most easily diag-
nosed serotype, based on its failure to ferment sorbitol
within 24 hours of incubation [17,18]. However, inrecent years, changes in diagnostic procedures have led to
the isolation of an increasing variety of non-O157 STEC
serogroups from HUS patients in Europe, including O26,
O91, O103, O111, O113, O121, O128, O145 and sorbitol-
fermenting O157 (SF O157) [4,7,8,14,19]. Recent outbreaks
of STEC infection in Europe, with varying degrees of HUS
development, have resulted in increased awareness. In
2011, E. coli O104 caused a large outbreak with many HUS
cases in Germany. While the majority of cases occurred
among adults, it also affected more children than previ-
ously seen in any other European outbreak to date [20]. In
Norway, a national outbreak of STEC O103:H25 occurred
in 2006, in which nine children developed HUS, including
one with fatal outcome [21,22], raising awareness among
physicians as well as microbiological laboratories.
Notification of EHEC infections to the Norwegian Surveil-
lance System for Communicable Diseases (MSIS) has been
mandatory since 1989 [18]. In Norway, all clinicians and
microbiological laboratories analyzing human specimens are
required by law to notify cases of group A infectious dis-
eases, such as STEC infection, to MSIS at the Norwegian
Institute of Public Health. Prior to the Norwegian outbreak
in 2006, notification was only required for HUS cases with
laboratory-confirmed STEC infection. In December 2006,
after the outbreak, notification criteria were changed to in-
clude all D+HUS cases, based solely on clinical presentation.
Since microbiological confirmation of STEC-HUS takes on
average 14 days (measured from the day the stool sample is
taken to the day the case is reported), the change in notifica-
tion criteria aimed to improve the timeliness of reporting. In
addition, clinically-based notification criteria were expected
to increase the sensitivity of the surveillance system, as de-
tection of STEC in a stool sample can be difficult and the
bacteria may not be present at the time a patient develops
HUS. Measures to improve diagnostic procedures were also
implemented after the 2006 outbreak, and the laboratories
methodology was gradually expanded to include PCR
screening for presence of stx at all the microbiological la-
boratories. After implementation, ring tests sent out to all
laboratories in the following years showed improved diag-
nostic capabilities for non-O157 serogroups.
The main aim of this study was to determine the annual
incidence of D+HUS among children <16 years of age
diagnosed in Norway from 1999 up to and including 2008
through a review of medical records, compare these numbers
with cases reported to MSIS, and consequently assess the
sensitivity of the D+HUS surveillance. The secondary aim
was to describe annual incidence and etiology of all types of
HUS in the same age group and for the same time period.
Methods
Design and data collection
We performed a retrospective, descriptive study. Data
were collected from medical records from 24 pediatric
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of age admitted from the 1st of January, 1999, to the 31st of
December, 2008. All hospitals with capacity and compe-
tence for supportive care of HUS and/or AKI patients were
included.
Potential cases were identified by performing medical
record searches for pediatric patients tagged with ICD-10
codes D59.3 (HUS), N17 (AKI) and/or N00/N01/N05
(acute nephritic syndrome/rapidly progressive nephritic
syndrome/unspecified nephritic syndrome). Apart from
D59.3, the diagnostic codes were investigated to identify
potentially misdiagnosed cases of HUS. Only cases match-
ing the case definitions were included, regardless of ICD-
10 code. Medical records were assessed in both electronic
and paper form. Data were registered in forms made in
EpiData (www.epidata.dk), which were designed through a
pilot project to determine the availability of desired vari-
ables in standard medical records. Data files were encry
pted according to the information security standards of the
Norwegian Institute of Public Health. Data on cases of
HUS and STEC notified from the 1st of January, 1999, to
the 31st of December, 2008, were exported from MSIS.
Population figures for children <16 years were acquired
from Statistics Norway (SSB).
Case definitions
A hemolytic-uremic syndrome (HUS) case was defined as:
– a case clinically compatible with all the following
laboratory findings of
o thrombocytopenia (<150 × 10^9/L)
AND
o anemia (Hgb < 10.5 g/dL)
▪ of hemolytic origin, with elevated serum
LD (>500 U/L)
ANDo acutely reduced renal function (serum
creatinine >35 μmol/L for patients < 1 years of
age, > 80 μmol/L for patients 1-15 years of age)
AND
o Either
▪ reported presence of fragmented red blood
cells (schiztocytes) on peripheral blood smear;
a sign of microangiopathic changes consistent
with hemolysis, an important part of HUS
pathophysiology [1]OR
▪ if peripheral blood smear was missing in the
journal; probable clinical HUS confirmed by
consulting a clinician with expertise in
pediatric nephrology.A diarrhea-associated HUS (D+HUS) case was defined
as a HUS case with either:– a clinical presentation of prodromal diarrhea, without
verifiable causative etiology (probable STEC-HUS).
or
– STEC-HUS, defined as a HUS case with laboratory-
verified STEC-infection.
A D-HUS case was defined as any non-diarrhea-
associated HUS cases of non-STEC causality.
Microbiology
Information on microbiological findings was gathered from
medical records and from MSIS for the notified cases. MSIS
receives data on microbiological characteristics from the re-
gional laboratories as well as from the National Reference
Laboratory for Enteropathogenic Bacteria in Norway.
Statistical analysis
Calculations were performed using Microsoft Excel.
Descriptive statistics are presented as proportions, median,
average and mean values with ranges and as incidence
rates, calculated using population numbers provided by
official registries.
Ethical considerations
The study was approved by the Regional Ethical Committee
South East A. Dispensation was granted from patient confi-
dentiality regulations as potential participants would only
be identifiable following the review of medical records. It
was therefore not necessary to contact all potential cases to
gain their consent prior to collecting journal data. However,
once cases were identified through the medical journal
review process, the parents were notified and could elect to
withdraw from the study. No patients chose this option.
Results
Sensitivity of the D+HUS and STEC surveillance
In the period 1999 up to and including 2008 28 HUS
cases among children <16 years of age were notified to
MSIS. Three cases, that is one case registered twice (two
different hospitals) in 2003, and one in 2007 were identi-
fied and excluded from this study as they were initially ad-
mitted to a hospital abroad. In the same period, 102 cases
of STEC infection were notified in the same age group.
We identified 23 cases of STEC-HUS in medical records
in the study period (Figure 1). Accordingly, 23% of the
STEC-cases notified to MSIS in the period were cases
with HUS.
Twenty of the HUS cases in MSIS were notified from the
start of the study period up to and including 2006, and five
after 2006. 17 of the cases notified before 2007 were identi-
fied as STEC-HUS cases; the remaining three were identi-
fied as probable STEC cases. These three were admitted to
hospital just before and after the outbreak in 2006, thus
probably notified as potential outbreak cases. The five cases
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Figure 1 HUS associated with STEC cases in children in Norway notified to MSIS between 1999 and 2008. Cases of shiga toxin producing
E. coli (STEC) infection reported to the Norwegian Communicable Disease Surveillance System, with share of cases identified in medical records as
associated to hemolytic-uremic syndrome (HUS) in children <16 years of age, Norway, 1999–2008 (n = 102).
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remaining STEC-HUS case, from 2005, was not notified to
MSIS. The corresponding numbers identified in the med-
ical records search were 33 and five for the period 1999–
2006 and 2007–2008, respectively (Table 1).
Incidence and etiology of all types of HUS in children
1999–2008
Based on information from the medical records, a total of
47 cases of HUS in children were identified from 24 differ-
ent Norwegian hospitals in the period 1999 to 2008
(Figures 2 and 3), varying from one case (in 2000) to 17
cases (in 2006) per year (Figure 3). Of the 47 HUS cases,
44 had the diagnostic code D59.3 (HUS). Three cases, two
probable STEC-HUS and one SP-HUS, were identified as
HUS through the diagnostic code for acute kidney injury
(AKI); N17. These were all recognized as HUS in the jour-
nal, but had been given the wrong diagnose code. All three
fit the inclusion criteria.
The average annual incidence rate of HUS of any eti-
ology was estimated to be 0.5 cases per 100,000 children
(range; lowest and highest year, respectively; 0.1-1.8).
Thirty-one (66%) were female. The incidence rate was
highest in children <5 years of age, with an estimatedTable 1 Diarrhea-associated HUS cases in children in
Norway notified and identified in children in Norway
Identified by/Year 1999-2006 2007-2008 Total
MSIS 20 5 25
Medical records 33 5 38
Proportion reported to surveillance 61% 100% 66%
Cases of diarrhea-associated hemolytic-uremic syndrome in children <16 years
of age reported to the Norwegian Communicable Disease Surveillance System
(MSIS) and identified through medical record search, Norway 1999–2008.average annual incidence rate of 1.3 cases per 100,000
children (range; lowest and highest year, respectively; 0.0-
3.8) (Table 2). The highest proportion of cases was in chil-
dren aged one year, accounting for 34% of the cases
(Table 2). The median age at initial admission was
29 months (range, 5 months-15 years).
Based on clinical presentation, cases were categorized
into 38 (81%) D+HUS cases and 9 (19%) D−HUS cases
(Figure 2). In the medical records, results from stool
examination were available for 43 (91%) patients and for
serological testing for 28 (60%) patients. STEC infection
was detected in 22 (51%) of the stool samples and seven
(25%) of the serological samples. One or both of these
tests were performed in 44 of the cases, and STEC infec-
tion was confirmed in 23 (52%) of them, thus in one case
STEC was only detected by serological testing.
Of the 38 D+HUS cases, 29 (76%) were sporadic and nine
(24%) were outbreak cases; all nine cases were from the
2006 outbreak. The estimated average annual incidence rate
for D+HUS was 0.4 per 100,000 children (range; lowest and
highest year, respectively; 0.0-1.4) (Table 2). Twenty-six
(68%) were female. The estimated average annual incidence
rate for D+HUS was highest among children <5 years of age
with 1.0 per 100,000 children (range; lowest and highest
year, respectively; 0.0-3.5). This group constituted 30 (79%)
of the D+HUS cases. STEC was confirmed in 23 (61%) of
the 38 D+HUS cases. The remaining 15 cases presented
with diarrhea, but without verified STEC infection or eti-
ology and thus classified as probable STEC-HUS. In these
cases, follow-up was evaluated in available medical records
for a minimum of 1.5 years from first hospital admittance;
none experienced recurrence of their HUS during this time.
The distribution of serotypes of STEC isolated from the
23 laboratory confirmed cases, is shown in Table 3.
Figure 2 Etiology of HUS in children in Norway. Etiological distribution of cases of hemolytic-uremic syndrome (HUS) in children <16 years of
age, Norway, 1999–2008 (n = 47).
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Figure 3 Yearly occurrence of HUS in children in Norway between 1999 and 2008. Yearly occurrence of cases of hemolytic-uremic syndrome
(HUS) in children <16 years of age, Norway, 1999–2008 (n = 47).
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Table 2 Epidemiology of HUS in children in Norway between 1999 and 2008
Type of HUS STEC-HUS Probable STEC-HUS Total D+HUS D-HUS All HUS
Measure
Cases (N) Cases (N) N % IR N % N % IR
Age
0-4 y 19 11 30 79 1.0 8 89 38 81 1.3
0 y 2 1 3 8 0.5 2 22 5 11 0.9
1 y 7 5 12 32 2.1 4 44 16 34 2.7
2 y 5 3 8 21 1.4 0 0 8 17 1.4
3 y 0 2 2 5 0.3 0 0 2 4 0.3
4 y 5 0 5 13 0.8 2 22 7 15 1.2
5-9 y 3 3 6 16 0.2 1 11 7 15 0.2
10-15 y 1 1 2 5 <0.1 0 0 2 4 <0.1
Total 23 15 38 100 0.4 9 100 47 100 0.5
Age-specific distribution (in number), proportion (in percentage) and incidence rate (IR; in average annual incidence rate in cases per 100,000 children) for
diarrhea-associated (D+HUS), with and without laboratory identified STEC infection (probable STEC-HUS) and the two combined, non-diarrhea-associated (D−HUS)
and all of the cases of hemolytic-uremic syndrome (all HUS) in children in Norway, 1999–2008 (N = 47).
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[21,22], O157 was the most common serogroup in-
volved in sporadic D+HUS, found in five cases (36%).
The remaining nine (64%) sporadic cases were non-
O157. Stx presence was reported in 12 (52%) of the 23
STEC-HUS cases, with stx2 present in 10 cases and
both stx1 and stx2 in two cases (Table 3). In the 11
cases where no stx was found, the strains isolated from
the patients were considered STEC that had lost their
toxin coding genes. Four of these strains were isolated
from outbreak cases, and Multiple-locus variable-
number tandem-repeats analysis (MLVA) genotyping of
the strains was used to categorize these as the causative
agent, even if they were stx negative [23].Table 3 Serology of STEC-related HUS in children in
Norway between 1999 and 2008
Case type –
toxin type Sporadic Epidemic
Shiga-
like
toxin 1
Shiga-
like
toxin 2
Both
shiga
like-toxin
1 and 2
Serotype
O26: H11 1 1
O26: H? 1 1
O87: H? 1
O103: H25 0 9 5
O103: H? 2
O145: H25 1
O145: H? 1
O157: H7 2 2
O157: H? 3 2
Non-O103/O157 2 1
Total 14 9 0 10 2
Distribution of serotype (O: cell wall antigen number, H: flagella antigen) and
shiga-like toxin profile in sporadic and epidemic cases of shiga toxin producing
E. coli-related hemolytic-uremic syndrome in children in Norway, 1999–2008 (N= 23).D−HUS/atypical HUS
Of the 47 identified HUS cases, 9 (19%) were considered
D−HUS. Five were male and four were female. Average an-
nual incidence rate was <0.1 per 100,000 children (range;
lowest and highest year, respectively; 0.0-0.3) (Table 2).
Eight (89%) of the nine children were <5 years of age, and
the last case was nine years. Two cases were related to
pneumococcal infection (SP-HUS) and three were of gen-
etic origin. All three patients had CD46-mutations. One
had an additional C3-mutation and another had anti-
bodies to factor H. In one case, Campylobacter was iso-
lated and specified as causative in the medical record,
without prodromal diarrhea. The remaining three were
non-diarrhea-associated cases with unknown etiology
(Figure 2).
Discussion
In the period 1st of January, 1999, to the 31st of December
2008, we identified a total of 47 cases of HUS in children
<16 years of age, with an estimated average annual inci-
dence rate of 0.5 cases per 100,000 children. Of these
cases, 81% were diarrhea-associated HUS (D+HUS),
though only 61% of these were laboratory verified with a
Shiga toxin-producing Escherichia coli (STEC) infection.
We also found that before mandatory notification criteria
were changed from D+HUS with laboratory verified STEC
infection to clinical D+ HUS in December 2006 [18], only
61% of D+HUS cases were notified. After the case defin-
ition was amended, the number of cases notified to MSIS
corresponds with the number of cases we found when sys-
tematically reviewing all patient medical records with rele-
vant ICD-10 codes.
We assume that all D+HUS cases reported via MSIS are
caused by STEC, since this is internationally recognized to
be the most common etiological agent in HUS cases
[12,18]. All D+HUS cases in our study are therefore coded
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found through our review of medical records had
laboratory-verified STEC. This may reflect that the
HUS cases were caused by other etiological agents causing
D+HUS that we were not able to recognize, but it is more
likely due to problems with diagnosing STEC in stool
samples from HUS patients. HUS typically develops as a
complication of STEC-related diarrhea, but patients often
no longer have diarrhea when they develop HUS and may
have stopped shedding the bacteria [1]. In addition, if the
patient has non-O157:H7 STEC, the diagnostic methods
are more complicated than if STEC is caused by O157:H7,
allowing the etiological agent to be overlooked. This is espe-
cially true for cases occurring before the outbreak in 2006,
as during that period many laboratories still based their
diagnostics on cultivation and could easily miss the diagno-
sis [18]. In our study, we found that 64% of verified STEC
cases were non-O157 when the outbreak-related STEC-
HUS cases are excluded. However, O157 was the most fre-
quently isolated serogroup causing sporadic HUS in
Norway, as has been found in other European countries
[6,7,10,11,14], South America [24,25] and North America
[15,26].
Based on surveillance data from MSIS, an estimated
23% of children with STEC infections developed HUS,
which is high in comparison to other countries; certain
studies have shown that 10%-15% of children infected
with STEC O157 develop HUS [6,12,26,27]. According to
the European Center for Disease Prevention and Control,
this proportion is about 8% [3]. However, these studies are
based predominantly on O157 STEC cases. In the 2012
Germany outbreak, where a particularly aggressive strain
of E. coli O104 was the cause, 22% of adults and a slightly
higher proportion of children (approximately 24%) devel-
oped HUS [20]. The high proportion of HUS cases
reported via MSIS may be explained by either an overesti-
mation of HUS cases, an underreporting of STEC cases,
or that STEC in Norway may be more likely to cause HUS
than what is described for O157 in the literature. The first
explanation is unlikely; in addition to the 23 confirmed
STEC-HUS cases, we also found 15 probable STEC-HUS,
all with classical clinical presentation of STEC-HUS.
When considering the difficulties described for laboratory
identification of non-O157:H7 STEC strains especially, it
is probable that several of these are actually STEC-HUS
cases. It is more likely that this high STEC-HUS/STEC-ra-
tio is due to underreporting of STEC cases. Mild cases of
STEC infection may only present with diarrhea, not re-
quiring medical attention or submission of stool samples.
Only severe cases, which are more likely to be compli-
cated by HUS, are investigated thoroughly for a source.
Isolation of STEC in D+HUS cases is also often dependent
on stool samples being examined early in the disease pro-
gression [18]. Additionally, the difficulties in identifyingnon-O157:H7 STEC strains may result in several cases be-
ing missed, despite samples being taken and analyzed. In
Norway, most of the cases are caused by non-O157:H7
STEC, and the virulence of non-O157:H7 strains is probably
variable. Some strains, like sorbitol-fermenting O157, are
now considered more likely to cause HUS than O157:H7
[28], whereas others might be less likely to cause HUS.
Although the proportion of STEC cases developing
HUS was high, the overall incidence rate of HUS reported
in our study is low compared to similar studies from other
European countries, [6-8,11,14], likely due to a low inci-
dence of diarrhea-associated HUS, since this accounts for
the majority of HUS in children (81%). This again points
to the low amount of STEC cases identified in this group
and the study as a whole. A possible explanation for this
may be the low prevalence of STEC among ruminants in
Norway. In particular, surveys in sheep and cattle have
found a low prevalence of O157 [18,29-31].
Our study also describes the burden and etiology of
atypical HUS in children. As there is no mandatory notifi-
cation of D−HUS cases in Norway, these cases were only
identified and described after our search through medical
records. Only nine D−HUS cases were identified in the ten
year period, accounting for less than 20% of the total HUS
burden in children. Of these, two were related to pneumo-
coccal infection (SP-HUS), three were of genetic origin,
one had a suspected associated with campylobacter infec-
tion and three were of unknown etiology. It is noteworthy
that there were only two SP-HUS cases during the ten
year period, as certain studies have indicated that this is
an increasing problem globally [32,33].
There are some limitations to our study. As it is retro-
spective, it reflects the judgments made by clinicians several
years ago, when HUS was relatively uncommon. A lack of
awareness could have led to misdiagnosed cases. However,
to minimize this we also searched for HUS cases in medical
records where patients were diagnosed as acute kidney in-
jury. We thereby identified three HUS cases without a HUS
ICD-10 code added by the clinicians, instead coded only as
acute kidney injury. Failure to detect STEC in HUS patients
due to late sampling and diagnostic problems in the labora-
tory are also limiting factors in the study, as the etiology
was not found in a notable proportion of cases.
Conclusions
Our findings indicate that the occurrence of HUS,
although low compared to other European countries,
and STEC in Norway is higher than previously assumed.
While we have no apparent explanation as to why the
incidence of HUS is low, a possible contributing factor
might be that the prevalence of STEC is low among ru-
minants, a known source of infection. The diagnostics
have improved after the outbreak in 2006. Despite this,
the results reinforce that clinicians should perform early
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pected. Therefore, our recommendation is to reinforce the
mandatory notification and surveillance of both D+HUS
and laboratory verified STEC-infections and to further
develop laboratory verification techniques of emerging
non-O157 STEC serotypes.
Our study also illustrates that the proportion of
laboratory verified HUS cases might be low. This high-
lights the need for surveillance based on clinical HUS
without the need for laboratory confirmation.
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